AFP and intrahepatic cholangiocarcinoma: Furthermore, 4 patients (26.7%) in the CHCC group had elevated CA19-9 and AFP levels, which was higher than 12 patients (2.1%) in the HCC group (P < .001) or 0 patient in the ICC group (P < .001).